Hologic Inc

Hologic Inc(HOLX)股票分析

$76.010

+0.365 (+0.48%)收盤時

Loading chart…
最高
76.070
開盤
76.010
成交量加權均價
76.03
成交量
102.03M
市值
17.32B
最低
76.000
成交金額
7.76B
企業價值/稅息折舊攤銷前利潤(TTM)
11.25

Hologic, Inc. is a medical technology company primarily focused on improving women's health and well-being through early detection and treatment. The Company is a developer, manufacturer and supplier of diagnostics products, medical imaging systems, and surgical products. Its segments include Diagnostics, Breast Health, GYN Surgical, and Skeletal Health. The Diagnostics segment offers a range of diagnostic products, which are used primarily to aid in the screening and diagnosis of human diseases. The Breast Health segment offers a broad portfolio of solutions for breast imaging, biopsy, breast surgery and pathology. The GYN Surgical segment's products include MyoSure hysteroscopic tissue removal system, NovaSure endometrial ablation system, Acessa ProVu laparoscopic radiofrequency ablation system, as well as CoolSeal vessel sealing portfolio and JustRight surgical stapler. The Skeletal Health segment's products include the Horizon DXA and the Fluoroscan Insight FD mini C-arm.

AI 分析 of Hologic Inc (HOLX)

持有

Hologic Inc (HOLX) does not present a compelling buy opportunity for a beginner investor with a long-term strategy at this time. While the technical indicators are mildly positive, the lack of significant positive catalysts, a recent analyst downgrade, and declining financial metrics suggest a cautious approach. Holding the stock or exploring other opportunities may be more prudent.

分析師評級(19)

上檔空間 +2.04%
買進
14 買進
5 持有
0 賣出
目前: 76.01
最低
76.00
平均
77.56
最高
79.00

Evercore ISI

2026-01-05

目標價

$78

In Line

BNP Paribas Exane

2025-11-21

目標價

$79

中性

Morgan Stanley

2025-11-10

目標價

$76

Equal Weight

Mizuho

2025-10-23

目標價

$78

中性

Stephens

2025-10-22

目標價

$76

Equal Weight

估值指標

Hologic Inc(HOLX)目前預期本益比為 16.36,5 年平均預期本益比為 18.08。

預期本益比

合理
5 年均值 P/E
18.08
目前P/E
16.36
高估
21.06
低估
15.09

預期 EV/EBITDA

低估
5 年均值 EV/EBITDA
13.44
目前EV/EBITDA
11.25
高估
15.31
低估
11.57

預期股價營收比

低估
5 年均值 P/S
4.26
目前P/S
3.53
高估
4.79
低估
3.72

Alphio AI 對 HOLX 的價格情境

情境價格取自當年最後一個月度預測區間。機率為固定的模型權重(25 / 50 / 25),不構成保證。

樂

樂觀

樂觀 · 25%HOLX

$90.01

情境價格

基

基準

基準 · 50%HOLX

$75.18

情境價格

悲

悲觀

悲觀 · 25%HOLX

$64.21

情境價格

持有 HOLX 的大戶

M

MIV Asset Management AG

+ 持有HOLX

+7.73%

3個月報酬率

T

Thematics Asset Management

+ 持有HOLX

+5.62%

3個月報酬率

M

Manulife Asset Management

+ 持有HOLX

+5.44%

3個月報酬率

C

Cinctive Capital Management LP

+ 持有HOLX

+3.28%

3個月報酬率

S

Soros Fund Management LLC

+ 持有HOLX

+3.17%

3個月報酬率

L

LMR Partners LLP

+ 持有HOLX

+2.60%

3個月報酬率

事件時間軸

2026-10-19 (ET)

16:00:00

Hologic Signs Agreement to Acquire Reveal Genomics

2026-06-16 (ET)

13:30:00

Hologic Wins in Germany, Siemens Prohibited from Selling Mammography Systems

2026-04-07 (ET)

09:30:00

Hologic Completes Acquisition by Blackstone and TPG, Valued at Up to $79 per Share

2026-04-06 (ET)

17:20:00

Blackstone and TPG Acquire Hologic, Deal Expected by April 7

資訊

HOLX 常見問題 —— 由 Alphio AI 解答

Hologic, Inc. is a medical technology company primarily focused on improving women's health and well-being through early detection and treatment. The Company is a developer, manufacturer and supplier of diagnostics products, medical imaging systems, and surgical products. Its segments include Diagnostics, Breast Health, GYN Surgical, and Skeletal Health. The Diagnostics segment offers a range of diagnostic products, which are used primarily to aid in the screening and diagnosis of human diseases. The Breast Health segment offers a broad portfolio of solutions for breast imaging, biopsy, breast surgery and pathology. The GYN Surgical segment's products include MyoSure hysteroscopic tissue removal system, NovaSure endometrial ablation system, Acessa ProVu laparoscopic radiofrequency ablation system, as well as CoolSeal vessel sealing portfolio and JustRight surgical stapler. The Skeletal Health segment's products include the Horizon DXA and the Fluoroscan Insight FD mini C-arm. It operates in the Healthcare sector (X-RAY APPARATUS & TUBES & RELATED IRRADIATION APPA industry).

Hologic Inc (HOLX) does not present a compelling buy opportunity for a beginner investor with a long-term strategy at this time. While the technical indicators are mildly positive, the lack of significant positive catalysts, a recent analyst downgrade, and declining financial metrics suggest a cautious approach. Holding the stock or exploring other opportunities may be more prudent.

19 analysts cover HOLX: 14 rate it Buy, 5 Hold and 0 Sell. The average price target is 77.56.

暫無貼文

註冊或登入後參與討論

本頁僅供研究參考,不構成投資建議。模型可能出錯。過往表現不代表未來結果。

開始交易